Journal of Chemotherapy最新文献

筛选
英文 中文
Predictors of olaparib discontinuation owing to adverse drug events in patients with ovarian, peritoneal, or fallopian tube cancer: a retrospective observational study. 卵巢癌、腹膜癌或输卵管癌患者因药物不良事件而停用奥拉帕利的预测因素:一项回顾性观察研究。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-04-01 Epub Date: 2024-05-02 DOI: 10.1080/1120009X.2024.2345025
Noriaki Kataoka, Takeo Hata, Kouichi Hosomi, Atsushi Hirata, Satoe Fujiwara, Emi Goto, Masami Nishihara, Masahide Ohmichi, Masashi Neo
{"title":"Predictors of olaparib discontinuation owing to adverse drug events in patients with ovarian, peritoneal, or fallopian tube cancer: a retrospective observational study.","authors":"Noriaki Kataoka, Takeo Hata, Kouichi Hosomi, Atsushi Hirata, Satoe Fujiwara, Emi Goto, Masami Nishihara, Masahide Ohmichi, Masashi Neo","doi":"10.1080/1120009X.2024.2345025","DOIUrl":"10.1080/1120009X.2024.2345025","url":null,"abstract":"<p><p>We investigated predictors of olaparib discontinuation owing to adverse effects. Patients with ovarian, peritoneal, or fallopian tube cancers treated with olaparib at Osaka Medical and Pharmaceutical University Hospital between April 2018 and September 2022 were included in this study. The exclusion criteria were as follows: discontinuation of treatment due to disease progression, use of anaemia medications, and use of cytochrome P450 (CYP3A4) inhibitors. The follow-up period was 90 d. Of the 46 eligible patients, 21 patients discontinued olaparib, including 15 patients with grade 3 or higher anaemia, eight patients with grade 3 or higher neutropenia, and four patients with non-haematological toxicity (including multiple onset). Multivariate logistic regression analysis showed that grade 4 neutropenia and anaemia progression to grades 2-3 due to chemotherapy administered before olaparib administration were predictors of olaparib discontinuation. The severity of neutropenia and anaemia due to chemotherapy before olaparib administration may be a potential marker for its discontinuation.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"168-174"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140849336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model. 基于群体药代动力学模型,对接受血液透析的肥胖患者进行万古霉素负荷剂量个体化。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-04-01 Epub Date: 2024-06-17 DOI: 10.1080/1120009X.2024.2367937
Lucie Polášková, Jan Miroslav Hartinger, Irena Murínová, Pavel Michálek, Ondřej Slanař, Martin Šíma
{"title":"Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model.","authors":"Lucie Polášková, Jan Miroslav Hartinger, Irena Murínová, Pavel Michálek, Ondřej Slanař, Martin Šíma","doi":"10.1080/1120009X.2024.2367937","DOIUrl":"10.1080/1120009X.2024.2367937","url":null,"abstract":"<p><p>This study aimed to develop a vancomycin population pharmacokinetic model in obese adult patients treated with intermittent haemodialysis and propose a model-based loading dose strategy ensuring attainment of newly recommended AUC-based PK/PD target. Retrospective cross-sectional analysis was performed among obese haemodialysis dependent adult patients treated with intravenous vancomycin. A pharmacokinetic population model was developed using a nonlinear mixed-effects modelling approach and Monte Carlo simulations were used to identify the optimal loading dose for PK/PD target attainment during the first 48 h of treatment. Therapeutic drug monitoring data from 27 patients with a BMI of 30.2-52.9 kg/m<sup>2</sup> were analysed. Among all tested variables, only LBM as a covariate of vancomycin Vd significantly improved the model, while vancomycin CL did not correlate with any of the tested variables. The median (IQR) value from the conditional mean of individual estimates of Vd and CL was 68.4 (56.6-84.2) L and 0.86 (0.79-0.90) L/h, respectively. To ensure optimal vancomycin exposure during the first 48 h of therapy, the vancomycin loading dose of 1500, 1750, 2000, 2250, 2500 and 2750 mg should be administered to obese patients with a lean body mass of ˂50, 50-60, 60-70, 70-80, 80-85 and >85 kg, respectively.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"121-129"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atorvastatin attenuates intestinal mucositis induced by 5-fluorouracil in mice by modulating the epithelial barrier and inflammatory response. 阿托伐他汀通过调节上皮屏障和炎症反应减轻5-氟尿嘧啶诱发的小鼠肠粘膜炎
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-04-01 Epub Date: 2024-05-06 DOI: 10.1080/1120009X.2024.2345027
Kátia Duarte Vital, Luiz Octavio Pires, Bruno Gallotti, Janayne Luihan Silva, Luís Cláudio Lima de Jesus, Jacqueline Isaura Alvarez-Leite, Ênio Ferreira, Vasco Ariston de Carvalho Azevedo, Flaviano Santos Martins, Valbert Nascimento Cardoso, Simone Odília Antunes Fernandes
{"title":"Atorvastatin attenuates intestinal mucositis induced by 5-fluorouracil in mice by modulating the epithelial barrier and inflammatory response.","authors":"Kátia Duarte Vital, Luiz Octavio Pires, Bruno Gallotti, Janayne Luihan Silva, Luís Cláudio Lima de Jesus, Jacqueline Isaura Alvarez-Leite, Ênio Ferreira, Vasco Ariston de Carvalho Azevedo, Flaviano Santos Martins, Valbert Nascimento Cardoso, Simone Odília Antunes Fernandes","doi":"10.1080/1120009X.2024.2345027","DOIUrl":"10.1080/1120009X.2024.2345027","url":null,"abstract":"<p><p>Chemotherapy-induced intestinal mucositis is a major side effect of cancer treatment. Statins are 3-hydroxy-3-methyl glutaryl coenzyme reductase inhibitors used to treat hypercholesterolemia and atherosclerotic diseases. Recent studies have demonstrated that atorvastatin (ATV) has antioxidant, anti-inflammatory, and resulting from the regulation of different molecular pathways. In the present study, we investigated the effects of ATV on intestinal homeostasis in 5-fluorouracil (5-FU)-induced mucositis. Our results showed that ATV protected the intestinal mucosa from epithelial damage caused by 5-FU mainly due to inflammatory infiltrate and intestinal permeability reduction, downregulation of inflammatory markers, such as <i>Tlr4, MyD88, NF-κB, Tnf-a, Il1β,</i> and <i>Il6</i> dose-dependent. ATV also improved epithelial barrier function by upregulating the mRNA transcript levels of mucin 2 (MUC2), and <i>ZO-1</i> and occludin tight junction proteins. The results suggest that the ATV anti-inflammatory and protective effects on 5-FU-induced mice mucositis involve the inhibition of the TLR4/MYD88/NPRL3/NF-κB, iNos, and caspase 3.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"175-192"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer. 基因多态性在乳腺癌新辅助化疗反应中的潜在作用。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-04-01 Epub Date: 2024-03-21 DOI: 10.1080/1120009X.2024.2330241
Om Elez Bouhniz, Abderraouf Kenani
{"title":"Potential role of genetic polymorphisms in neoadjuvant chemotherapy response in breast cancer.","authors":"Om Elez Bouhniz, Abderraouf Kenani","doi":"10.1080/1120009X.2024.2330241","DOIUrl":"10.1080/1120009X.2024.2330241","url":null,"abstract":"<p><p>Chemoresistance leads to treatment failure, which can arise through different mechanisms including patients' characteristics. Searching for genetic profiles as a predictor for drug response and toxicity has been extensively studied in pharmacogenomics, thus contributing to personalized medicine and providing alternative treatments. Numerous studies have demonstrated significant evidence of association between genetic polymorphisms and response to neoadjuvant chemotherapy (NAC) in breast cancer. In this review, we explored the potential impact of genetic polymorphisms in NAC primary resistance through selecting a specific clinical profile. The genetic variability within pharmacokinetics, pharmacodynamics, DNA synthesis and repair, and oncogenic signaling pathways genes could be predictive or prognostic markers for NAC resistance. The clinical implication of these results can help provide individualized treatment plans in the early stages of breast cancer treatment. Further studies are needed to determine the genetic hosts of primary chemoresistance mechanisms in order to further emphasize the implementation of genotypic approaches in personalized medicine.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"97-111"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer. HER2阳性晚期乳腺癌患者接受吡罗替尼加曲妥珠单抗与不同线化疗的预后效果比较
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-04-01 Epub Date: 2024-04-01 DOI: 10.1080/1120009X.2024.2335714
Yangqingqing Zhou, Hui Wang, Jiao Yang, Fan Wang, Danfeng Dong, Xiaoai Zhao, Le Wang, Ruiyuan He, Zhiping Ruan, Jin Yang
{"title":"Comparison of the prognostic effect of pyrotinib plus trastuzumab and chemotherapy different lines therapy in HER2-positive advanced breast cancer.","authors":"Yangqingqing Zhou, Hui Wang, Jiao Yang, Fan Wang, Danfeng Dong, Xiaoai Zhao, Le Wang, Ruiyuan He, Zhiping Ruan, Jin Yang","doi":"10.1080/1120009X.2024.2335714","DOIUrl":"10.1080/1120009X.2024.2335714","url":null,"abstract":"<p><p>This study aimed to compare the efficacy of pyrotinib, trastuzumab combined with chemotherapy with different lines therapy in human epidermal growth factor receptor 2- (HER2-) positive advanced breast cancer (ABC) and analyze the factors affecting the prognosis. A total of 84 patients with median age of 49 year-old. The mPFS of patients receiving first-line pyrotinib plus trastuzumab and chemotherapy was the longest (11 months) compared with second- and third line patients (<i>p</i> = 0.106). The objective response rate (ORR) and disease control rate (DCR) of the total population were 33.3% and 82.1% respectively. Subgroup analysis suggested that using pyrotinib plus trastuzumab and Albumin-bound paclitaxel was not inferior to combine with Vinorelbine in regards of PFS. Histological grade (OR: 0.233[0.069 ∼ 0.781], <i>p</i> = 0.018) and tumor location (OR: 0.286[0.087 ∼ 0.942], <i>p</i> = 0.040) were independent factors influencing the ORR. Multivariate cox analysis showed that Ki-67 was independently associated with increased risk of progression (HR: 1.843[1.044-3.254], <i>p</i> = 0.035). The most common adverse events were diarrhea (17.9%) and neutropenia (11.9%). In the first-, second- and third-line treatment, pyrotinib plus trastuzumab and chemotherapy is effective and safe. Pyrotinib and trastuzumab combined with Albumin-bound paclitaxel may be a potential ideal treatment plan for HER2-positive advanced breast cancer.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"135-145"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140335806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19. 将抗病毒联合疗法作为对持续感染 COVID-19 的免疫功能低下宿主的拯救疗法。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-04-01 Epub Date: 2024-06-14 DOI: 10.1080/1120009X.2024.2367935
Roberta Maria Antonello, Davide Marangoni, Filippo Ducci, Anna Barbiero, Tommaso Manciulli, Lucia Graziani, Nicoletta Di Lauria, Lorenzo Menicacci, Lorenzo Paci, Benedetta Sordi, Lorenzo Zammarchi, Alessandro Morettini, Sara Tomassetti, Gian Maria Rossolini, Alessandro Bartoloni, Michele Spinicci
{"title":"Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19.","authors":"Roberta Maria Antonello, Davide Marangoni, Filippo Ducci, Anna Barbiero, Tommaso Manciulli, Lucia Graziani, Nicoletta Di Lauria, Lorenzo Menicacci, Lorenzo Paci, Benedetta Sordi, Lorenzo Zammarchi, Alessandro Morettini, Sara Tomassetti, Gian Maria Rossolini, Alessandro Bartoloni, Michele Spinicci","doi":"10.1080/1120009X.2024.2367935","DOIUrl":"10.1080/1120009X.2024.2367935","url":null,"abstract":"<p><p>The management of severe/prolonged SARS-CoV-2 infections in immunocompromised hosts is still challenging. We describe nine patients with hematologic malignancies with a history of unsuccessful SARS-CoV-2 treatment receiving antiviral combination treatment for persistent infection at a tertiary hospital in central Italy (University Hospital of Careggi, Florence). Combination treatments consisted of nirmatrelvir/ritonavir plus molnupiravir (<i>n</i> = 4), nirmatrelvir/ritonavir plus remdesivir (<i>n</i> = 4) or remdesivir plus molnupiravir (<i>n</i> = 1) for 10 days, in some cases associated with sotrovimab. Combinations were generally well tolerated. One patient obtained viral clearance but died due to the underlying disease. In eight cases, clinical and virological success was confirmed by radiological follow-up. Antivirals combination is likely to become a mainstay in the future management of COVID-19 among immunocompromised patients, but knowledge in this field is still very limited and prospective studies on larger cohorts are urgently warranted.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"130-134"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare immune-related adverse effect of pembrolizumab: pulmonary hypertension. pembrolizumab罕见的免疫相关不良反应:肺动脉高压。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-04-01 Epub Date: 2024-05-08 DOI: 10.1080/1120009X.2024.2349858
Caner Acar, Gökhan Sahin, Haydar Çagatay Yüksel, Burçak Karaca
{"title":"Rare immune-related adverse effect of pembrolizumab: pulmonary hypertension.","authors":"Caner Acar, Gökhan Sahin, Haydar Çagatay Yüksel, Burçak Karaca","doi":"10.1080/1120009X.2024.2349858","DOIUrl":"10.1080/1120009X.2024.2349858","url":null,"abstract":"<p><p>Pembrolizumab is an immune checkpoint inhibitor that acts <i>via</i> PD-1 blockade. Recent studies have shown its effectiveness in treating various solid organ tumours. However, unlike cytotoxic chemotherapeutic agents, pembrolizumab may cause immune-related adverse effects. These immune-related adverse effects are generally mild, although patients who experience grade-three or higher side effects may require hospitalisation. In particular, cardiopulmonary side effects are associated with high mortality rates. We report the case of a 24-year-old female patient with alveolar soft part sarcoma accompanied by rare and difficult-to-treat pulmonary hypertension induced by pembrolizumab.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"193-198"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140876565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial. 甲氧卡培他滨和来曲唑联合治疗激素受体阳性、HER2 阴性的转移性乳腺癌:随机 II 期试验。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-04-01 Epub Date: 2024-05-20 DOI: 10.1080/1120009X.2024.2342741
Hamdy A Azim, Mariam A Saleh, Passant Essam Eldin, Ahmed A M Abdelhafeez, Mohamed Hassan, Loay Kassem
{"title":"Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial.","authors":"Hamdy A Azim, Mariam A Saleh, Passant Essam Eldin, Ahmed A M Abdelhafeez, Mohamed Hassan, Loay Kassem","doi":"10.1080/1120009X.2024.2342741","DOIUrl":"10.1080/1120009X.2024.2342741","url":null,"abstract":"<p><p>First line endocrine therapy is the gold standard for advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Adding CDK4/6 inhibitors has improved progression free survival. Metronomic Capecitabine has proven to be safe to combine with endocrine therapy with promising efficacy. We conducted a phase II randomized, open label, single centre clinical trial on patients with metastatic ER positive and HER 2 negative breast cancer. Eligible patients were randomized (1:1) to arm A: metronomic dose of capecitabine (500 mg/m<sup>2</sup> BID) combined with letrozole (2.5 mg OD) or arm B: letrozole single agent. The primary endpoint was progression free survival. The study was terminated early due to poor accrual and 60 eligible patients out of the planned 204 were randomized. This clinical trial is registered on ClinicalTrials.gov (MD-127-2019, NCT04571437). Between February 2019 and April 2022, 60 patients were randomized. This is the first report of the study, after a median follow-up of 18.6 months. The median age at diagnosis was 47 years with only 41.7% of patients post-menopausal. Half of our patients had bone-only disease, 45% had visceral metastasis (liver and lung) and 63% presented with endocrine sensitive disease. The estimated median PFS for the whole population was 16.2 months. Median PFS for capecitabine arm was 17.7 months versus 14.6 months for letrozole alone (<i>p</i> = 0.078). Overall response rate was 70% for capecitabine/letrozole arm and 56.6% for letrozole only. Clinical benefit rate was 90% in the capecitabine/letrozole arm versus 73.3% in the letrozole arm. Overall survival data is still immature after this short follow up duration. Adverse event assessment showed acceptable all grade and high grade toxicity profile consistent with the established adverse events of both capecitabine and letrozole. Anaemia (28.3%) and hand & foot syndrome (43.8%) were significantly more common in the capecitabine/letrozole arm. Capecitabine combined with letrozole have showed a trend towards improvement in progression free survival with potential more benefit to certain sub-groups and the combination showed acceptable safety profile consistent with the established known safety profile of both letrozole and capecitabine.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"159-167"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141065443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical scoring model for predicting cefotaxime-resistance in Klebsiella pneumoniae bacteremia: development and validation based on portal of entry. 预测肺炎克雷伯菌菌血症中头孢他啶耐药性的临床评分模型:基于入口的开发和验证。
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-04-01 Epub Date: 2024-05-23 DOI: 10.1080/1120009X.2024.2357052
Hyoung-Tae Kim, Cheon-Hoo Jeon, Si-Ho Kim, Yu Mi Wi
{"title":"Clinical scoring model for predicting cefotaxime-resistance in <i>Klebsiella pneumoniae</i> bacteremia: development and validation based on portal of entry.","authors":"Hyoung-Tae Kim, Cheon-Hoo Jeon, Si-Ho Kim, Yu Mi Wi","doi":"10.1080/1120009X.2024.2357052","DOIUrl":"10.1080/1120009X.2024.2357052","url":null,"abstract":"<p><p>We developed a prediction model for cefotaxime resistance in patients with <i>K. pneumoniae</i> bacteremia. Adult patients with <i>K. pneumoniae</i> bacteremia were grouped into derivation (from March 2018 to December 2019) and validation (from January 2020 to August 2020) cohorts. The prediction scoring system was based on factors associated with cefotaxime resistance identified by the logistic regression model. A total of 358 patients were enrolled (256 for derivation, 102 for validation). In the multivariable analysis, age ≥65 years, hospital-acquired infection, prior antimicrobial use, and an updated Charlson comorbidity index ≥3 points were associated with cefotaxime resistance in the derivation cohort. When each variable was counted as 1 point, the values of the area under the curve were 0.761 in the derivation and 0.781 in the validation cohorts. The best cutoff value using the Youden index was ≥2 with 73.6% sensitivity and 67.5% specificity. Our simple scoring system favorably predicted cefotaxime resistance.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"112-120"},"PeriodicalIF":1.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes in breast cancer patients: a systematic review study.
IF 1.9 4区 医学
Journal of Chemotherapy Pub Date : 2025-02-28 DOI: 10.1080/1120009X.2025.2468044
Ali Tayebi, Adnan TizMaghz, Mahmood Gorjizad, Arian Tavasol, Ali Tajaddini, Fariborz Rashnoo, Kimia Vakili, Mohsen Behmanesh, Faranak Olamaeian, Mohammadjavad Ashoori
{"title":"Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes in breast cancer patients: a systematic review study.","authors":"Ali Tayebi, Adnan TizMaghz, Mahmood Gorjizad, Arian Tavasol, Ali Tajaddini, Fariborz Rashnoo, Kimia Vakili, Mohsen Behmanesh, Faranak Olamaeian, Mohammadjavad Ashoori","doi":"10.1080/1120009X.2025.2468044","DOIUrl":"https://doi.org/10.1080/1120009X.2025.2468044","url":null,"abstract":"<p><p>As a systematic review, this study addresses a gap in the literature by evaluating both the short-term and long-term outcomes of breast cancer patients undergoing neoadjuvant chemotherapy (NAC). The purpose of the current study was to evaluate NAC's impact on breast cancer patients' surgical outcomes. We performed a comprehensive search of international databases, including PubMed, Scopus, Embase, and Science Direct, covering studies from 2000 to 2023, using carefully selected keywords. Our search strategy aimed to capture a wide variety of relevant studies. To ensure a structured and unbiased selection, we followed PRISMA guidelines throughout the process. We concentrated on identifying studies that reported on short-term outcomes, like surgical complications (e.g., operation time, blood loss), as well as long-term outcomes, including overall survival, tumor size reduction, metastasis rates, breast conservation surgery, and recurrence rates. The findings highlighted the benefits of NAC in terms of lower recurrence and metastasis rates. The results also emphasized the significance of considering tumor characteristics and nodal involvement for prognostication in this patient population. The findings of this study will contribute to a better understanding of the impact of NAC on surgical outcomes in breast cancer patients, providing valuable insights for treatment planning and optimizing patient care.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-14"},"PeriodicalIF":1.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信